How GLP-1 Weight-Loss Medicines Work

Hunger can make a simple instruction—eat a little less—feel anything but simple. You may know what you intended to eat and still finish a meal wanting more.

GLP-1 medicines act on signals involved in appetite. For some people, treatment can mean feeling less hungry and more satisfied after eating. That change helps explain how medication can make a difference when advice about food has not been enough. Research on appetite and semaglutide

Your body already makes GLP-1

GLP-1 stands for glucagon-like peptide-1. It is a hormone your intestines release in response to food. Among its jobs, it helps the pancreas release insulin when blood sugar rises and influences how quickly food leaves the stomach. These effects helped make GLP-1 a target for diabetes treatment. NIH explanation

The hormone also influences appetite. Semaglutide activates GLP-1 receptors—the parts of cells that receive the signal. These receptors are found in brain regions involved in appetite regulation. Semaglutide reduces calorie intake, an effect thought to work through appetite. Wegovy prescribing information

The body's own GLP-1 breaks down quickly. Medicines were developed to keep acting for longer, making sustained treatment possible. This is why the treatment can influence eating beyond the brief hormonal response to a single meal. NIH explanation

Why eating can feel different

Researchers have studied appetite as well as weight. In a small, 20-week randomized trial involving 72 adults with obesity, people receiving weekly semaglutide injections, gradually increased to 2.4 mg, reported less hunger and greater fullness than those receiving placebo. They also reported fewer or weaker food cravings. The study was funded by the manufacturer, Novo Nordisk. Read the study

For someone who responds that way, stopping a meal can feel easier because the desire to keep eating has changed. That is a different experience from deciding to stop while still feeling hungry. The findings help explain a possible treatment experience; they do not mean everyone will feel the same change.

These medicines can also slow the movement of food out of the stomach. That is one part of their action, but it does not explain everything about weight loss. For example, tirzepatide's prescribing information says this slowing is greatest after the first dose and diminishes over time. Zepbound prescribing information

The names describe different medicines

Wegovy contains semaglutide, which activates GLP-1 receptors. Zepbound contains tirzepatide, which activates both GLP-1 and another hormone receptor called GIP. Their prescribing details differ. Wegovy information, Zepbound information

Wegovy is available as injections and tablets. The formulation matters: the ingredient name alone does not tell you how a product is used. Wegovy information

What those changes can mean for weight

In the 68-week STEP 1 trial, 1,961 adults without diabetes who had obesity, or overweight with a weight-related health condition, received weekly semaglutide injections at a target dose of 2.4 mg or placebo. The estimated average weight loss was 14.9% with semaglutide and 2.4% with placebo. Both groups received lifestyle support. This manufacturer-funded trial tested a particular regimen; its average is not a forecast for an individual or for every GLP-1 product. STEP 1 trial

Side effects also matter. Nausea, vomiting, diarrhea, and constipation are common with semaglutide and tirzepatide. Serious risks include pancreatitis, gallbladder problems, and dehydration-related kidney injury. Certain histories rule them out, including a personal or family history of medullary thyroid cancer or having MEN 2, a rare inherited condition. A previous serious allergic reaction to a product's ingredients also rules that product out. Wegovy information, Zepbound information

Treatment involves more than a prescription

A clinician needs to consider medical history, other medicines, pregnancy plans, likely benefits, and costs. Nutrition, physical activity, and follow-up remain part of care. Treatment may continue long term if it is helping and the risks remain acceptable; some weight regain is common after stopping. NIDDK treatment guidance

Before starting, it is worth understanding what follow-up will look like: who will help with side effects, how progress will be assessed, and what happens if the treatment is difficult to tolerate or afford. Those conversations connect the science of appetite to the practical question of whether a medicine fits your life.